You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州(06160.HK)與Strand Therapeutics達成mRNA療法戰略合作
阿思達克 01-12 11:15
百濟神州(06160.HK)公布,與生物製藥公司Strand Therapeutics達成合作,雙方將共同開發和商業化Strand新型、多功能mRNA療法於實體瘤的治療。百濟神州已獲得在亞洲(除日本以外)、澳洲和新西蘭開發和商業化至多兩款腫瘤免疫項目的選擇權,項目將利用Strand的瘤內或全身性傳遞機制,將具備改變腫瘤微環境能力的mRNA直接傳遞至腫瘤病灶。

百濟神州高級副總裁兼外部創新負責人羅侶松預計,合作有助公司在抗腫瘤領域推出新型的基於mRNA的腫瘤免疫療法。根據協議條款,Strand將獲得500萬美元的現金預付款,同時可獲得共計至多2,800萬美元的額外近期付款,以及銷售里程碑及授權地區的分級產品銷售特許使用費。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account